MDR1 C3435T Polymorphism in Patients with Breast Cancer

Turgut, Sebahat; Yaren, Arzu; Kursunluoglu, Raziye; Turgut, Günfer

doi:10.1016/j.arcmed.2007.02.005

Cited by 63 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in contrast with other studies, although the literature on the 'functional' effects of SNPs in the MDR1 gene is replete with contradictory findings (52). Turgut et al demonstrated a 1.5-fold increased risk for development of breast cancer in T allele carriers, in a study with 57 patients and 50 healthy subjects in a Turkish population (36). In the present study, T allele in cases was slightly higher than in controls, but this finding was not significant.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study

Henríquez-Hernández

Murias-Rosales²,

González³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Breast cancer (BC) is a complex disease influenced by environmental and genetic factors. The disease has important genetic and environmental components, most of them are still unknown. An important role of gene polymorphisms related to the risk of developing BC has been reported. However, the results have been controversial. We investigated the association of TSER, MTHFR C677T, p53 codon 72 and MDR1 C3435T gene polymorphisms with breast carcinoma in women from Canary Islands (Spain). Blood samples collected from 135 patients with BC and 304 healthy controls all of them Caucasian, were analyzed through polymerase chain reaction-restriction fragment length polymorphism. Subsequently, a structured questionnaire including patient history and risk factors in relation to BC development was filled out. Allelic frequencies of these genetic variations were: TSER, (2) 0.55 and (3) 0.45 in cases, 0.49 and 0.51 respectively in controls (P=0.240); MTHFR C677T, (C) 0.63 and (T) 0.37 in cases, 0.60 and 0.40 respectively in controls (P=0.568); p53 Arg72Pro, (Arg) 0.74 and (Pro) 0.26 in cases and controls (P=0.910); MDR1 C3435T, (C) 0.52 and (T) 0.48 in cases, 0.55 and 0.45 respectively in controls (P=0.523). We did not observe any gene polymorphism as a risk factor to develop BC. A statistical association was observed between p53 codon 72 polymorphism and family history of breast cancer in both groups, as well as between MDR1 C3435T and smoking habits in cases (P<0.05). Gene polymorphisms vary by regions. The present study contributes to the characterization of the genetic pattern of the Canary population.

show abstract

Section: Discussionmentioning

confidence: 70%

“…C3435T polymorphism in the MDR1 gene may limit the local detoxification activity in breast tissue and be a risk factor for cancer development and behaviour (35). Different studies have been associated this polymorphism in MDR1 gene with smoking, high body mass index and risk of BC (35,36).…”

Section: Introductionmentioning

confidence: 99%

Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study

Henríquez-Hernández

Murias-Rosales²,

González³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Our results are consistent with the hypothesis that the T allele (generally associated with lower MDR1 expression and PGP function) offers less protection from the accumulation of carcinogenic materials in tissues with documented MDR1 expression. Similarly, Turgut et al 22 found higher T allele frequency in breast cancer patients in comparison to controls (P ¼ 0.009). Our results were gained in contrast to work carried out by other researchers, who observed no significant differences in genotype and allele frequencies between Iranian patients with breast cancer and control subjects (P ¼ 0.744 and 0.590, respectively).…”

Section: Discussionmentioning

confidence: 77%

“…14,[18][19][20][24][25][26] Several studies have considered the relationship between MDR1 expression and C3435T polymorphism examining clinical and pathological characteristics in patients with breast cancer. 11,22,23 However, the correlation was either nonsignificant or there was insufficient data. A significant association between patients with DIC and lobular invasive carcinoma was observed (T vs C: P ¼ 0.024) in the group we tested.…”

Section: Discussionmentioning

confidence: 99%

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

et al. 2009

View full text Add to dashboard Cite

P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P ¼ 0.024, 0.014, 0.006, respectively, w 2 -test or Fisher's exact test). We also found significantly higher (P ¼ 0.019, w 2 -test) T allele frequency in breast cancer patients (n ¼ 221) than in controls (n ¼ 113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n ¼ 38; P ¼ 0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n ¼ 102; P ¼ 0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.

show abstract

“…Clinical-pathological formation can result in several cancer types (Trock et al, 1997;Tatari et al, 2009;Rao et al, 2010;Sabahi et al, 2010;Mhaidat et al, 2011). Several studies have investigated the association of the C3435T polymorphism with breast cancer development, prognosis, and treatment outcome; however, the inconsistent and contradicting evidence has led to a confused picture (Turgut et al, 2007;Huang et al, 2008;Rodrigues et al, 2008;George et al, 2009;Taheri et al, 2010;Chen et al, 2012). In the present study, we analyzed the MDR1 C3435T polymorphism in Mexican women with IDBC or FCC as compared with healthy women.…”

Section: Resultsmentioning

confidence: 99%

MDR1 C3435T polymorphism in Mexican patients with breast cancer

et al. 2014

View full text Add to dashboard Cite

ABSTRACT. We investigated whether the MDR1 C3435T polymorphism is associated with fibrocystic changes (FCC), infiltrating ductal breast cancer (IDBC), and/or clinical-pathological features of IDBC in Mexican patients. Samples from women who received surgical treatment in 2007 at the Centro Médico de Occidente (México) were included in the analysis. Genotyping was performed by polymerase chain reaction-restricted fragment length polymorphisms in 64 paraffin-embedded breast samples with IDBC, 64 samples with FCC, and 183 peripheral blood samples of healthy females designated as the healthy group (HG). The frequency of the T allele was 41, 45, and 52% for the FCC, IDBC, and HG samples, respectively. Significant differences were only found between the FCC The prevalence of the T/T genotype was 8, 13, and 24% for FCC, IDBC, and HG samples, respectively. Again, statistical differences were only found between FCC and HG samples for the T/T genotype (OR = 0.28, 95%CI = 0.106-0.77; P = 0.009). Although the T allele and the T/T genotype were less frequent in the IDBC group than in the HG, the differences were not significant. Furthermore, no associations were found between the C3435T polymorphism and clinical-pathological features of the IDBC group. Both the FCC and IDBC groups had a high frequency of the C allele relative to the HG in this sample of women from Western Mexico.

show abstract

MDR1 C3435T Polymorphism in Patients with Breast Cancer

Cited by 63 publications

References 21 publications

Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study

Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study

MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

MDR1 C3435T polymorphism in Mexican patients with breast cancer

Contact Info

Product

Resources

About